Abstracts

CARDIOVASCULAR DISEASE AMONGST PEOPLE LIVING WITH HIV IN AFRICA

Cardiovascular disease (CVD), and particularly atherosclerotic and thrombotic disease, is an emerging concern amongst people living with HIV (PLWHIV) in Africa. Although AIDS defining illnesses still account for majority of admissions to hospital and in critical care areas, the proportion of Non-Communicable diseases (NCDs) is significantly rising. Similarly, in the outpatient setting, cardiovascular (CV) risk…

NEUTRALIZING ANTIBODY DEVELOPMENT DURING HIV-1 INFECTION

A preventative HIV vaccine is likely to require broadly neutralizing antibodies (bNAbs) able to recognize diverse circulating viruses from across the world. Such antibodies have not yet been elicited by vaccination. However some HIV-1-infected individuals naturally mount bNAb responses during chronic infection, suggesting a need for prolonged maturation towards breadth. Longitudinal studies of how bNAbs…

IMMUNOGEN DESIGN TO INDUCE HIV NEUTRALIZING ANTIBODIES

Induction of broadly neutralizing antibodies (bnAbs) is a major HIV vaccine goal. We hypothesize that consistent bnAb elicitation will require ‘germline-targeting’ priming immunogens, to activate bnAb precursor B cells, and structure-guided, or ‘reductionist’, boosting immunogens, to shepherd antibody maturation toward bnAb development. To test this hypothesis, we have focused our initial immunogen design work on…

STRUCTURAL STUDIES OF HIV NEUTRALIZING ANTIBODIES

The HIV envelope glycoprotein (Env) trimer on the surface of the virus is the sole target of broadly neutralizing antibodies. Soluble, native-like Env trimers, particularly those of the SOSIP design, have recently been developed and enabled high-resolution structural studies as well as opportunities for protein subunit vaccination with bona fide trimers. A number of labs…

CLINICAL STUDIES WITH BROADLY NEUTRALIZING ANTIBODIES

Clinical Studies with Broadly Neutralizing Antibodies Michel C. Nussenzweig AIDS is a preventable disease. Nevertheless, according to UNAIDS, 2.1 million of individuals were infected with HIV-1 in 2015 worldwide. An effective vaccine is highly desirable. Most vaccines in clinical use today prevent infection because they elicit antibodies that block pathogen entry. Consistent with this general…

HIV-1 DRUG RESISTANCE IN RESOURCE-LIMITED SETTINGS

Introduction: The global scale up of cART has now reached 17 million treated individuals, largely in LMICs. Antiretroviral therapy (ART) is pivotal for controlling HIV-1 infection through widescale treatment as prevention (TasP) and pre-exposure prophylaxis (PreP). Pre treatment drug resistance to NNRTI is associated with a 2-3 fold higher viral failure rate in both high…

LONG-ACTING ANTIRETROVIRAL THERAPY: A SHOT IN THE DARK OR A PARADIGM SHIFT?

Long-acting and extended-release (LA/ER) formulations of antiretroviral drugs have the potential to revolutionize treatment and prevention. Formulations in current development run the gamut from oral products capable of delivering effective systemic anti-HIV drug concentrations for 7-14 days after a single dose, to implants capable of providing effective treatment for as long as 6, and possibly…